Chapter 1: Preface

• 1.1 Report Description

• 1.2 Scope of the Study

• 1.3 Research Objectives

• 1.4 Key Assumptions

• 1.5 Currency and Measurements Used in the Report

Chapter 2: Executive Summary

• 2.1 Global Adult Vaccines Market — Snapshot

• 2.2 Key Findings by Segment

• 2.3 Key Findings by Region

• 2.4 Analyst Recommendations

Chapter 3: Market Overview and Introduction

• 3.1 Introduction to Adult Vaccines

  • 3.1.1 Definition and Concept of Adult Immunization

  • 3.1.2 Differentiation Between Pediatric and Adult Vaccine Programs

  • 3.1.3 Role of Adult Vaccines in Preventive Healthcare and Disease Control

  • 3.1.4 Overview of Vaccine-Preventable Diseases in the Adult Population

• 3.2 Historical Development and Milestones

  • 3.2.1 Evolution of Adult Immunization Programs Globally

  • 3.2.2 Impact of COVID-19 Pandemic on Adult Vaccination Awareness and Infrastructure

  • 3.2.3 Landmark Approvals: Shingrix, Prevnar, Abrysvo, Arexvy and Other Key Adult Vaccines

• 3.3 Regulatory and Standards Landscape

  • 3.3.1 FDA Regulatory Framework for Adult Vaccine Approval and Labeling

  • 3.3.2 EMA and European Regulatory Pathways for Adult Immunization Products

  • 3.3.3 WHO Expanded Programme on Immunization (EPI) and Global Advisory Committee on Vaccine Safety (GACVS)

  • 3.3.4 CDC Adult Immunization Schedule and ACIP Recommendation Framework

  • 3.3.5 PMDA (Japan) and Asia-Pacific Regulatory Considerations

  • 3.3.6 Regulatory Pathways for mRNA, Recombinant, and Next-Generation Adult Vaccine Platforms

• 3.4 Value Chain Analysis

  • 3.4.1 Antigen and Adjuvant Raw Material Suppliers

  • 3.4.2 Vaccine Manufacturers and Contract Development and Manufacturing Organizations (CDMOs)

  • 3.4.3 Cold Chain Logistics and Distribution Networks

  • 3.4.4 National Immunization Programs and Public Procurement Agencies

  • 3.4.5 Retail and Hospital Pharmacy Dispensing Networks

  • 3.4.6 End Users: Adults, Healthcare Workers, Travelers, and Geriatric Population

Chapter 4: Market Dynamics

• 4.1 Market Drivers

  • 4.1.1 Rising Geriatric Population and Immunosenescence Increasing Demand for Adult Vaccines

  • 4.1.2 Increasing Government Vaccination Campaigns, National Immunization Schedules, and Awareness Programs

  • 4.1.3 High Unmet Need for Immunization Against RSV, Shingles, and Pneumococcal Disease in Adults

  • 4.1.4 Expansion of mRNA and Recombinant Vaccine Platforms into Adult Indications

  • 4.1.5 Growing Adoption of Combination and Multivalent Vaccines Improving Convenience and Coverage

  • 4.1.6 Post-COVID-19 Normalization of Adult Immunization Behavior and Healthcare Engagement

  • 4.1.7 Rising Burden of Chronic Diseases (Diabetes, COPD, Cardiovascular Disease) Increasing Vaccine-Preventable Complication Risk

  • 4.1.8 Expanding Insurance Reimbursement and Payer Coverage for Adult Vaccines in High-Income Markets

  • 4.1.9 Increasing Corporate Wellness Programs and Occupational Health Vaccination Mandates

  • 4.1.10 Advancing Adjuvant Technology Improving Immunogenicity in Older Adult Populations

• 4.2 Market Restraints

  • 4.2.1 Vaccine Hesitancy and Misinformation Undermining Adult Immunization Uptake

  • 4.2.2 High Out-of-Pocket Costs and Limited Reimbursement in Low- and Middle-Income Countries

  • 4.2.3 Cold Chain and Logistics Challenges in Emerging and Rural Markets

  • 4.2.4 Limited Adult Immunization Infrastructure Compared to Well-Established Pediatric Programs

  • 4.2.5 Regulatory Complexity and Extended Approval Timelines for Novel Adult Vaccine Formulations

  • 4.2.6 Uneven Distribution of GAVI and International Funding Across Adult vs. Pediatric Vaccine Programs

• 4.3 Market Opportunities

  • 4.3.1 Rapid Commercialization of RSV Vaccines for Adults (Abrysvo, Arexvy) Creating a New Market Category

  • 4.3.2 Growing Demand for Travel Vaccines and Pre-Exposure Prophylaxis Among Adults

  • 4.3.3 Emerging Market Expansion in Asia-Pacific, Latin America, and Middle East

  • 4.3.4 Integration of AI and Digital Health Tools for Vaccine Tracking, Reminder Systems, and Coverage Monitoring

  • 4.3.5 Increasing Pharmaceutical Investment in Therapeutic Vaccine Pipelines (Cancer Vaccines, Alzheimer's, CMV)

  • 4.3.6 Public-Private Partnerships Supporting National Adult Immunization Strategy Rollouts

  • 4.3.7 Label Expansion and New Adult Indications for Approved Vaccine Platforms

• 4.4 Market Challenges

  • 4.4.1 Overcoming Deep-Rooted Perception That Vaccines Are Only for Children

  • 4.4.2 Supply Chain Constraints and Seasonal Demand Fluctuations for Influenza Vaccines

  • 4.4.3 Price Pressure from Generic and Biosimilar Vaccine Entrants in Mature Markets

  • 4.4.4 Lack of Harmonized Adult Immunization Schedules Across Countries and Regions

• 4.5 Porter's Five Forces Analysis

  • 4.5.1 Bargaining Power of Buyers

  • 4.5.2 Bargaining Power of Suppliers

  • 4.5.3 Threat of New Entrants

  • 4.5.4 Threat of Substitutes

  • 4.5.5 Competitive Rivalry

• 4.6 PEST Analysis

  • 4.6.1 Political Factors

  • 4.6.2 Economic Factors

  • 4.6.3 Social Factors

  • 4.6.4 Technological Factors

Chapter 5: Global Adult Vaccines Market — By Vaccine Type

• 5.1 Overview and Definition

• 5.2 Monovalent Vaccines

  • 5.2.1 Market Overview

  • 5.2.2 Single Antigen Vaccines and Specific Disease Vaccines

  • 5.2.3 Market Attractiveness and Growth Analysis

• 5.3 Multivalent / Combination Vaccines

  • 5.3.1 Market Overview

  • 5.3.2 Combination Vaccines and Multi-Antigen Vaccine Platforms

  • 5.3.3 Bivalent and Quadrivalent Formulations for Influenza and HPV

  • 5.3.4 Market Attractiveness and Growth Analysis

Chapter 6: Global Adult Vaccines Market — By Technology

• 6.1 Overview and Definition

• 6.2 Live Attenuated Vaccines

  • 6.2.1 Market Overview

  • 6.2.2 Applications: Varicella Zoster, MMR, and Other Live Attenuated Adult Vaccines

  • 6.2.3 Market Attractiveness and Growth Analysis

• 6.3 Inactivated Viral and Bacterial Vaccines

  • 6.3.1 Market Overview

  • 6.3.2 Applications: Influenza (Inactivated), Hepatitis A, Polio, and Others

  • 6.3.3 Market Attractiveness and Growth Analysis

• 6.4 Toxoid Vaccines

  • 6.4.1 Market Overview

  • 6.4.2 Applications: Tetanus and Diphtheria Toxoid Components (TdaP/Td)

  • 6.4.3 Market Attractiveness and Growth Analysis

• 6.5 Recombinant, Subunit, and Conjugate Vaccines

  • 6.5.1 Market Overview

  • 6.5.2 Applications: HPV (Gardasil), Hepatitis B, Shingrix, Prevnar, and RSV Vaccines (Abrysvo, Arexvy)

  • 6.5.3 Market Attractiveness and Growth Analysis

• 6.6 mRNA Vaccines

  • 6.6.1 Market Overview

  • 6.6.2 Applications: COVID-19 Boosters, Emerging mRNA-Based Influenza and RSV Vaccine Pipelines

  • 6.6.3 Market Attractiveness and Growth Analysis

• 6.7 Other Technologies

  • 6.7.1 Viral Vector Vaccines

  • 6.7.2 DNA Vaccines and Novel Adjuvanted Platforms

Chapter 7: Global Adult Vaccines Market — By Disease Indication

• 7.1 Overview and Definition

• 7.2 Influenza

  • 7.2.1 Market Overview

  • 7.2.2 Standard Dose, High-Dose, and Adjuvanted Formulations for Adults

  • 7.2.3 Seasonal Demand Dynamics and Annual Reformulation Cycle

  • 7.2.4 Market Attractiveness and Growth Analysis

• 7.3 Zoster (Shingles)

  • 7.3.1 Market Overview

  • 7.3.2 Shingrix (RZV) and Live Zoster Vaccine (ZVL) Comparative Analysis

  • 7.3.3 Adoption in Adults Aged 50 and Above

  • 7.3.4 Market Attractiveness and Growth Analysis

• 7.4 Pneumococcal Disease

  • 7.4.1 Market Overview

  • 7.4.2 PCV (Prevnar) and PPSV (Pneumovax) Vaccine Adoption in Adults

  • 7.4.3 Evolving CDC/ACIP Recommendations and Clinical Practice Impact

  • 7.4.4 Market Attractiveness and Growth Analysis

• 7.5 Human Papillomavirus (HPV / Cervical Cancer)

  • 7.5.1 Market Overview

  • 7.5.2 Gardasil and Cervarix Adoption in Adult Females and Males

  • 7.5.3 Catch-Up Vaccination Programs for Adults

  • 7.5.4 Market Attractiveness and Growth Analysis

• 7.6 Hepatitis (A and B)

  • 7.6.1 Market Overview

  • 7.6.2 Hepatitis A Vaccine Use in Travelers, High-Risk Adults, and Healthcare Workers

  • 7.6.3 Hepatitis B Vaccination in Adult Healthcare Professionals and Chronic Disease Populations

  • 7.6.4 Market Attractiveness and Growth Analysis

• 7.7 Tetanus, Diphtheria, and Pertussis (TdaP / Td)

  • 7.7.1 Market Overview

  • 7.7.2 Booster Dosing in General Adult Population and Maternal Immunization

  • 7.7.3 Occupational Health and Healthcare Worker Mandates

  • 7.7.4 Market Attractiveness and Growth Analysis

• 7.8 Respiratory Syncytial Virus (RSV)

  • 7.8.1 Market Overview

  • 7.8.2 Abrysvo (Pfizer) and Arexvy (GSK) Commercial Landscape

  • 7.8.3 Target Adult Population: Adults Aged 60+ and High-Risk Adults

  • 7.8.4 Market Attractiveness and Growth Analysis

• 7.9 Meningococcal Disease

  • 7.9.1 Market Overview

  • 7.9.2 MenACWY and MenB Vaccine Use in College Students, Military, and Travelers

  • 7.9.3 Market Attractiveness and Growth Analysis

• 7.10 Measles, Mumps, and Rubella (MMR)

  • 7.10.1 Market Overview

  • 7.10.2 Adult MMR Catch-Up Immunization and Outbreak Response Programs

  • 7.10.3 Market Attractiveness and Growth Analysis

• 7.11 Varicella (Chickenpox)

  • 7.11.1 Market Overview

  • 7.11.2 Adult Varicella Vaccination for Susceptible Individuals

  • 7.11.3 Market Attractiveness and Growth Analysis

• 7.12 COVID-19 Booster Vaccines

  • 7.12.1 Market Overview

  • 7.12.2 Updated mRNA Booster Landscape and Annual Immunization Behavior

  • 7.12.3 Market Attractiveness and Growth Analysis

• 7.13 Travel and Miscellaneous Vaccines

  • 7.13.1 Typhoid, Yellow Fever, Japanese Encephalitis, and Rabies Vaccines

  • 7.13.2 Market Overview and Demand from International Travelers

  • 7.13.3 Market Attractiveness and Growth Analysis

Chapter 8: Global Adult Vaccines Market — By Distribution Channel

• 8.1 Overview and Definition

• 8.2 Hospital Pharmacy

  • 8.2.1 Market Overview

  • 8.2.2 In-Patient and Out-Patient Vaccine Administration in Hospital Settings

  • 8.2.3 Market Attractiveness and Growth Analysis

• 8.3 Retail Pharmacy and Drug Stores

  • 8.3.1 Market Overview

  • 8.3.2 Role of Chain Pharmacies in Expanding Adult Vaccine Access

  • 8.3.3 Walk-In Immunization and Pharmacist-Led Vaccination Services

  • 8.3.4 Market Attractiveness and Growth Analysis

• 8.4 Government and Public Health Immunization Centers

  • 8.4.1 Market Overview

  • 8.4.2 National Immunization Programs and Mass Vaccination Campaign Infrastructure

  • 8.4.3 Market Attractiveness and Growth Analysis

• 8.5 Other Distribution Channels

  • 8.5.1 Corporate Wellness and Occupational Health Programs

  • 8.5.2 Travel Clinics and International Healthcare Facilities

  • 8.5.3 Online and Telepharmacy-Based Vaccine Access Platforms

Chapter 9: Global Adult Vaccines Market — By End User

• 9.1 Overview and Definition

• 9.2 Hospitals

  • 9.2.1 Market Overview

  • 9.2.2 Inpatient and Outpatient Adult Immunization Programs in Hospital Networks

  • 9.2.3 Market Attractiveness and Growth Analysis

• 9.3 Specialty and Primary Care Clinics

  • 9.3.1 Market Overview

  • 9.3.2 Primary Care Physician and Internal Medicine-Led Adult Vaccination Programs

  • 9.3.3 Geriatric and Infectious Disease Specialty Clinic Adoption

  • 9.3.4 Market Attractiveness and Growth Analysis

• 9.4 Healthcare Firms and Managed Care Organizations

  • 9.4.1 Market Overview

  • 9.4.2 Employer-Sponsored and Managed Care Adult Immunization Benefits

  • 9.4.3 Market Attractiveness and Growth Analysis

• 9.5 Other End Users

  • 9.5.1 Military and Defense Health Services

  • 9.5.2 Universities, Colleges, and Educational Institution Health Programs

Chapter 10: Global Adult Vaccines Market — By Region

• 10.1 Overview

• 10.2 North America

  • 10.2.1 Market Overview

  • 10.2.2 United States

    • 10.2.2.1 By Disease Indication

    • 10.2.2.2 By Technology

    • 10.2.2.3 By Distribution Channel

  • 10.2.3 Canada

  • 10.2.4 Mexico

• 10.3 Europe

  • 10.3.1 Market Overview

  • 10.3.2 Germany

  • 10.3.3 United Kingdom

  • 10.3.4 France

  • 10.3.5 Italy

  • 10.3.6 Spain

  • 10.3.7 Switzerland

  • 10.3.8 Russia

  • 10.3.9 Rest of Europe

• 10.4 Asia Pacific

  • 10.4.1 Market Overview

  • 10.4.2 China

  • 10.4.3 Japan

  • 10.4.4 India

  • 10.4.5 South Korea

  • 10.4.6 Australia

  • 10.4.7 Southeast Asia (Indonesia, Vietnam, Malaysia, Thailand, Philippines)

  • 10.4.8 Rest of Asia Pacific

• 10.5 Latin America

  • 10.5.1 Market Overview

  • 10.5.2 Brazil

  • 10.5.3 Mexico

  • 10.5.4 Argentina

  • 10.5.5 Rest of Latin America

• 10.6 Middle East and Africa

  • 10.6.1 Market Overview

  • 10.6.2 Saudi Arabia

  • 10.6.3 United Arab Emirates

  • 10.6.4 South Africa

  • 10.6.5 Egypt, Nigeria, and Turkey

  • 10.6.6 Rest of Middle East and Africa

Chapter 11: Vaccines and Regulatory Interventions

• 11.1 Key Regulatory Approvals and Policy Decisions Shaping the Adult Vaccines Market

  • 11.1.1 FDA Approvals: RSV Vaccines for Adults, Updated COVID-19 Booster Authorizations

  • 11.1.2 EMA and European Commission Regulatory Decisions on Adult Vaccines

  • 11.1.3 ACIP and CDC Recommendations: Adult Immunization Schedule Updates

• 11.2 Government Funding and Procurement Programs for Adult Immunization

  • 11.2.1 US Medicare and Medicaid Vaccine Coverage Expansions

  • 11.2.2 National Vaccination Strategies in EU Member States

  • 11.2.3 WHO and UNICEF Comprehensive Multi-Year Plan (cMYP) for Adult Immunization

• 11.3 Mergers, Acquisitions, and Licensing in the Vaccine Industry

  • 11.3.1 Recent M&A Activity and Strategic Consolidation in Vaccine Manufacturing

  • 11.3.2 Licensing and Technology Transfer Agreements for mRNA and Adjuvant Platforms

Chapter 12: Vaccine Products and Pipeline

• 12.1 Approved Adult Vaccine Products — Global Overview

  • 12.1.1 Influenza Vaccine Portfolio (Standard, High-Dose, Adjuvanted, Recombinant)

  • 12.1.2 Shingrix (Zoster Vaccine Recombinant, Adjuvanted) — GSK

  • 12.1.3 Abrysvo (RSV Vaccine) — Pfizer

  • 12.1.4 Arexvy (RSV Vaccine) — GSK

  • 12.1.5 Prevnar Family (Pneumococcal Conjugate Vaccines) — Pfizer and Merck

  • 12.1.6 Gardasil and Cervarix (HPV Vaccines) — Merck and GSK

  • 12.1.7 COVID-19 Updated Boosters — Moderna, Pfizer-BioNTech, Novavax

• 12.2 Late-Stage Pipeline for Adult Vaccines

  • 12.2.1 Next-Generation Influenza Vaccines (Universal Flu Vaccine Research)

  • 12.2.2 mRNA-Based RSV and Influenza Combination Vaccine Candidates

  • 12.2.3 Therapeutic Cancer Vaccine Candidates and Prophylactic CMV Programs

  • 12.2.4 Alzheimer's Disease Vaccine Research (Emerging Programs)

Chapter 13: Competitive Landscape

• 13.1 Market Concentration and Competitive Intensity Mapping

• 13.2 Market Share Analysis of Leading Players

• 13.3 Competitive Benchmarking Framework

  • 13.3.1 Adult Vaccine Portfolio Breadth and Disease Indication Coverage

  • 13.3.2 mRNA and Recombinant Technology Platform Capabilities

  • 13.3.3 Geographic Commercialization Reach and Market Penetration

  • 13.3.4 R&D Investment and Late-Stage Pipeline Strength

  • 13.3.5 Regulatory Approval Track Record Across Key Markets

  • 13.3.6 Strategic Partnerships, In-Licensing, and M&A Activity

• 13.4 Key Recent Developments

  • 13.4.1 Product Launches and Regulatory Approvals

  • 13.4.2 Clinical Trial Milestones and Phase III Data Readouts

  • 13.4.3 Acquisitions, Mergers, and Licensing Agreements

  • 13.4.4 Collaborations, Partnerships, and Joint Ventures

  • 13.4.5 Manufacturing Capacity Expansions and CDMO Partnerships

Chapter 14: Company Profiles

The final report includes a complete list of companies

• GlaxoSmithKline plc (GSK)

  • Company Overview

  • Financial Performance

  • Product Portfolio

  • Strategic Initiatives

  • SWOT Analysis

• Pfizer Inc.

• Sanofi Pasteur

• Merck & Co., Inc.

• AstraZeneca plc

• Moderna, Inc.

• Johnson & Johnson (Janssen Vaccines)

• CSL Limited (Seqirus)

• Novavax, Inc.

• Serum Institute of India Pvt. Ltd.

• Bharat Biotech International Limited

• Indian Immunologicals Ltd.

• Biological E. Limited

• Dynavax Technologies Corporation

• Valneva SE

Chapter 15: Appendix

• Research Methodology Detail

  • Secondary Research Sources

  • Primary Research Approach

  • Data Triangulation and Validation Process

  • Assumptions and Limitations

• List of Abbreviations

• List of Tables and Figures

• Related Market Reports

Chapter 16: Disclaimer